Cosmax (192820) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
20 Feb, 2026Executive summary
Q4 2024 saw robust growth in Korea and Southeast Asia, slow recovery in China, and negative growth in the US.
Net profit turned positive year-over-year, with significant improvement in operating profit margin.
Strong demand for indie brands and exports drove Korea's performance, while Southeast Asia benefited from local brand preference and export growth.
Financial highlights
Q4 2024 consolidated sales reached 558.0 KRW bn, up 27.8% year-over-year.
Operating profit rose 76.8% to 39.8 KRW bn; net profit turned positive at 12.9 KRW bn.
Gross profit increased 40.2% to 108.0 KRW bn; OPM hit a record 7.2% for Q4.
COGS ratio was 82.8%, SG&A cost ratio 8.2%, aided by a 2bn bad debt reversal.
Outlook and guidance
Continued strong demand expected in Korea and Southeast Asia.
China market remains challenging but shows signs of improvement, especially in Guangzhou.
US outlook cautious due to order delays and slow new client ramp-up.
Latest events from Cosmax
- Record Q2 2026 revenue and profit growth driven by skincare and US turnaround.192820
Q2 2026 - Q1 2026 revenue up 15.9% YoY and net profit up 312.1%, driven by Korea and China growth.192820
Q1 2026 - Strong revenue and profit growth in 4Q 2025, led by health supplement and holding segments.192820
Q4 2025 - Revenue up 1.0% YoY, but profit declined on one-off costs; R&D and ESG efforts remain strong.192820
Q3 2025 - H1 2025 revenue hit KRW 1,212.1B, with net profit impacted by non-operating expenses.192820
Q2 2025 - Korea and Southeast Asia drove robust profit growth, offsetting China and US weakness.192820
Q3 2024 - H1 2024 revenue reached ₩1,078.3B with net income of ₩54.9B, led by Korea and Southeast Asia growth.192820
Q2 2024 - Q1 2025 revenue and operating profit grew, but net profit fell due to one-off and non-operating losses.192820
Q1 2025